Mayo Clinic Medical School, Rochester, MN, USA.
Curr Oncol Rep. 2012 Aug;14(4):307-10. doi: 10.1007/s11912-012-0236-x.
To date, the published literature describes 18 reports of nasal septal perforation in cancer patients with the administration of bevacizumab. This complication was detected during post-marketing surveillance of bevacizumab. How should patients who develop this complication be managed? This discussion summarizes suggestions for management of bevacizumab-associated nasal septal perforation and, as relevant to healthcare providers, discusses some of the practical aspects of post-marketing pharmacovigilance.
迄今为止，已发表的文献描述了 18 例接受贝伐珠单抗治疗的癌症患者发生鼻中隔穿孔的报告。这一并发症是在贝伐珠单抗上市后监测中发现的。对于发生这种并发症的患者应如何进行管理？本文总结了贝伐珠单抗相关性鼻中隔穿孔的处理建议，并结合上市后药物警戒的实际情况，为医疗保健提供者提供了一些相关讨论。
